Acute myeloid leukemia
What Is Acute Myeloid Leukemia?
Acute myeloid leukemia is a blood cancer in which clonal neoplastic myeloid progenitor cells proliferate uncontrollably within the bone marrow and, in some cases, in tissue outside the marrow, causing failure of normal blood cell production.1
According to the World Health Organization, detecting more than twenty percent of bone marrow cells as myeloid blasts is diagnostic for acute myeloid leukemia, distinguishing it from related but less aggressive bone marrow disorders.1
Treatment for acute myeloid leukemia has evolved rapidly over the past decade as improved understanding of the cytogenetic and molecular drivers of the disease has refined prognosis and enabled development of targeted therapeutics.2
Treatment for AML has evolved rapidly over the last decade as improved understanding of cytogenetic and molecular drivers of leukemogenesis refined survival prognostication and enabled development of targeted therapeutics.
National Center for Biotechnology Information
Symptoms
Patients typically present with symptoms related to bone marrow failure, including fatigue, headaches, or shortness of breath resulting from anemia.3
Excessive or unexplained bleeding and bruising, caused by low platelet counts, along with frequent infections related to low neutrophil counts, are also common presenting features.3
Additional symptoms can include bone pain, pale skin, and fever, reflecting the broad impact of impaired blood cell production throughout the body.3
Causes
Acute myeloid leukemia arises when genetic changes accumulate within myeloid progenitor cells, disrupting normal maturation and allowing abnormal cells to multiply while crowding out healthy blood cell production.1
Specific molecular abnormalities, including mutations affecting the FLT3 and NPM1 genes, play a central role in disease development and have become key targets for modern treatment strategies.2
Interestingly, NPM1 mutated protein can also appear on the surface of leukemia cells, an observation that has opened new possibilities for immune based therapies designed to specifically recognize and target this mutation.4
Risk Factors
Smoking, previous chemotherapy treatment for another cancer, and exposure to radiation may all increase the risk of developing acute myeloid leukemia.3
Additional risk factors include advancing age, certain inherited genetic syndromes, and exposure to specific industrial chemicals, all of which can contribute to the genetic changes underlying the disease.3
A preceding myelodysplastic phase or history of secondary leukemia also raises risk and is associated with a less favorable disease course compared to acute myeloid leukemia arising without such a history.1
Complications
The most important prognostic factor in acute myeloid leukemia is the leukemia cell karyotype, meaning the pattern of chromosomal abnormalities present within the cancer cells.1
Favorable karyotypes are associated with better outcomes, while negative prognostic factors include increasing age, a preceding myelodysplastic phase, secondary leukemia, high white blood cell count at diagnosis, and absence of specific microscopic features called Auer rods.1
Complications of the disease itself and its treatment can include severe infection, bleeding, and organ dysfunction related to profound suppression of normal bone marrow function.3
Treatment
Molecularly targeted therapies are now approved specifically for FLT3 and IDH1/2 mutated acute myeloid leukemia, reflecting a shift toward precision treatment based on each patient’s individual tumor biology.2
Gilteritinib, a FLT3 inhibitor, is used for newly diagnosed FLT3 mutated acute myeloid leukemia, while oral azacitidine has been shown to improve survival in patients with NPM1 and or FLT3 mutated disease.2
Emerging immune based approaches that target NPM1 as a cell surface marker represent a promising new direction in treatment, potentially offering additional options for patients whose leukemia carries this specific mutation.4
Prevention
Because most cases of acute myeloid leukemia result from genetic changes that occur spontaneously within bone marrow cells, there is no reliable way to prevent the disease in most patients.
Avoiding known risk factors where possible, including tobacco use and unnecessary occupational exposure to certain industrial chemicals, may help reduce individual risk to some degree.3
Early diagnosis and treatment remain key to achieving a good prognosis and cure in most patients, making prompt medical evaluation of concerning symptoms especially important.3
Why Visual Communication Matters for Acute Myeloid Leukemia
Explaining how specific molecular mutations drive leukemia development, and how targeted therapies interrupt these pathways, requires visuals that make complex genetic and cellular concepts accessible.
Pharmaceutical companies, hematology oncology practices, and research institutions rely on precise illustration and animation to communicate acute myeloid leukemia biology and treatment mechanisms.
- Illustrating clonal myeloid progenitor proliferation within the bone marrow
- Animating FLT3 and NPM1 mutation biology and downstream signaling effects
- Explaining the mechanism of action of targeted therapies such as gilteritinib
- Visualizing karyotype based risk stratification and prognosis
- Supporting patient education on diagnosis, treatment, and disease monitoring
- Creating training materials for hematology oncology clinicians
How Biotic Artlab Supports Acute Myeloid Leukemia Communication
We work with pharmaceutical companies, hematology oncology practices, and research organizations to create scientifically accurate visuals that make acute myeloid leukemia biology and treatment easier to understand.
- Custom 3D animations of myeloid progenitor cell biology and mutation pathways
- Detailed illustrations of FLT3 and NPM1 targeted therapy mechanisms
- Mechanism of action animations for emerging immune based treatments
- Patient facing materials on diagnosis, karyotype testing, and treatment options
- Clinical training content for hematology oncology teams
- Conference presentations and marketing visuals for leukemia research audiences
Frequently Asked Questions
What is acute myeloid leukemia?
It is a blood cancer caused by uncontrolled proliferation of abnormal myeloid progenitor cells within the bone marrow.1
What are common symptoms of acute myeloid leukemia?
Fatigue, easy bruising or bleeding, frequent infections, bone pain, and fever are common presenting symptoms.3
What role do FLT3 and NPM1 mutations play?
These are key molecular abnormalities that drive disease development and now serve as targets for modern precision therapies.2
What is the most important prognostic factor?
The leukemia cell karyotype, meaning the pattern of chromosomal abnormalities present, is the most important prognostic factor.1
How is acute myeloid leukemia treated?
Treatment often includes intensive chemotherapy, and for patients with specific mutations, targeted therapies such as FLT3 inhibitors.2
Can acute myeloid leukemia be prevented?
There is no reliable way to prevent most cases, though avoiding known risk factors such as smoking may help reduce individual risk somewhat.3
Have a Project in Mind? Contact Us.
If you are developing patient education materials, clinical training content, or marketing visuals related to acute myeloid leukemia, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.
References
- National Center for Biotechnology Information. Acute Myeloid Leukemia, Genetic Alterations and Their Clinical Prognosis.
- National Center for Biotechnology Information. Molecularly Targeted Therapy in Acute Myeloid Leukemia, Current Treatment Landscape and Mechanisms of Response and Resistance.
- National Cancer Institute. Acute Myeloid Leukemia Treatment.
- National Center for Biotechnology Information. Cell Surface Surprise, NPM1 Is an Immune Therapy Target for Acute Myeloid Leukemia.
Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, or individualized advice from a qualified healthcare professional.